A Phase 3 interventional study of nilotinib and imatinib in Myelogenous Leukemia, Chronic, sponsored by Novartis Pharmaceuticals. Completed at 213 sites in 35 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one has the largest enrollment, is one of 3 that started in 2007, is one of 15 in phase 3, and was the 6th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 846 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 2nd largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2007, is one of 19 in phase 3, and was the 24th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).
An extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.
Primary objectives of this study:
The Primary objectives of Extension Phase of the study:
The study was designed to determine whether the treatment of newly diagnosed, previously untreated Ph+ CML-CP patients with either nilotinib 300 mg bid or 400 mg bid demonstrated improved efficacy compared to imatinib 400 mg qd. The primary efficacy endpoint was the rate of MMR defined as the proportion of patients who achieved ≥ 3 log reduction in BCR-ABL transcripts compared to either the standardized Baseline established in the IRIS trial (International Randomized Interferon versus STI571) (Cortes et al 2005) or to the BCR-ABL ratio ≤ 0.1% by International Scale, as detected by real-time quantitative polymerase chain reaction (RQ-PCR) at 12 months.
The key secondary endpoint was to compare the rate of durable MMR between nilotinib 300 mg bid with that of imatinib, and of nilotinib 400 mg bid with that of imatinib at 24 months. This report presents the final results of efficacy and safety at the LPLV (21-Aug-2019).
The main data analysis was done at the time when all patients completed 12 cycles of treatment (or discontinued earlier). There were two primary comparisons at this time point: the MMR rate of nilotinib 400 mg versus the MMR rate of imatinib 400 mg, and the MMR rate of the nilotinib 300 mg versus the MMR rate of the imatinib 400 mg. Comparisons were done sequentially, i.e. the MMR rate of nilotinib 400 mg versus the MMR rate of imatinib 400 mg was to be compared first; if it was significant at 5% level, the MMR rate of the nilotinib 300 mg versus the MMR rate of the imatinib 400 mg was to be compared. The study had a 90% power to detect a 15% difference between the nilotinib 400 mg arm versus imatinib 400 mg arm assuming that the MMR rate of imatinib is 40% and the MMR rate of nilotinib is 55%. The study also had a 90% power to detect a 15% difference between the nilotinib 300 mg and the imatinib 400 mg arms, if the comparison between the nilotinib 400 mg and the imatinib 400 mg was significant.
The second main data analysis was done at the time when all patients completed 24 cycles of treatment (or discontinued earlier). There were two key comparisons at this time point: the rate of durable MMR at 24 months of the nilotinib 400 mg versus the imatinib 400 mg, and the rate of durable MMR at 24 months of the nilotinib 300 mg versus the imatinib 400 mg.
In order to control the overall type I error rate at or below 5%, only when the corresponding comparison on the primary efficacy endpoint(s) was (were) significant, the key secondary comparison(s) of the respective nilotinib doses (400 mg bid and/or 300 mg bid) versus imatinib 400 mg qd were tested at two-sided 5% significance level.
Patients participating after demonstrating suboptimal response/treatment failure to their assigned study treatment in the core study were offered the option to continue in the extension study and to receive imatinib 400 mg bid (option available only until protocol amendment 7) or nilotinib therapy at a dose of 400 mg bid.
Key Inclusion criteria:
Key Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: nilotinib
Drug: nilotinib
Drug: imatinib
Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
Also known as: AMN107
Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
Also known as: STI571
Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.
Time frame: Baseline, 12 months
Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.
Time frame: 12 months
Rates of Durable MMR at 24 Months Between All 3 Arms
Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.
Time frame: 24 months
Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months
CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as "Nocomplete cytogenetic response".
Time frame: 12, 24, 36, 48, 60, 72 months (M)
Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.
Time frame: 12 months
Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.
Time frame: 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months
Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib
Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)
Time frame: at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months
Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib
This is the molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)
Time frame: at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months
Time to First MMR
Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.
Time frame: up to 84 months
Duration of MMR
Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.
Time frame: approx. 11 years
Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts
Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.
Time frame: up to 84 months
Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts
It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.
Time frame: approx. 11 years
Rate of Hematologic Response
Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).
Time frame: 12 months, 24 months, Overall on Core study (approx. 11 years)
Time to Complete Cytogenic Response (CCyR)
Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR
Time frame: 24 months
Duration of CCyR
Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.
Time frame: up to 72 months
Progression-free Survival (PFS)
Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study
Time frame: approx. 11 years
Event-free Survival (EFS)
Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR
Time frame: approx. 11 years
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.
Time frame: approx. 11 years
Actual Dose-intensity
Actual dose intensity is defined as total dose over time on treatment
Time frame: approx. 11 years
Time to Progression to AP/BC
Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.
Time frame: approx. 11 years
Pharmacokinetics: Cmax
Cmax is defined as the maximum serum concentration after dose
Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Pharmacokinetics: Cmin
Cmin is defined as the minimum serum concentration after dose
Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Pharmacokinetics: Tmax
Tmax is defined as the sampling time when maximum measured serum concentration occurs
Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Pharmacokinetics: AUC0-last
AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method
Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).
Time frame: Overall for Extension study for approx. 10 years
Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.
Time frame: Overall for Extension study for approx. 10 years
Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))
Time frame: Overall for Extension study for approx. 10 years
Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)
Time frame: Overall for Extension study for approx. 10 years
Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)
Time frame: Overall for Extension study for approx. 10 years
Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)
This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.
Time frame: Overall for Extension study for approx. 10 years
The study over-enrolled, and 846 patients (283 in the imatinib 400 mg arm, 282 in the nilotinib 300 mg arm and 281 in the nilotinib 400 mg arm) were randomized. DP = disease progression, SOR/TF = Suboptimal response or treatment failure
| Milestone | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Started | 283 | 282 | 281 |
| Safety analysis set | 280 | 279 | 277 |
| Discon. core/did not enter ext. | 235 | 256 | 278 |
| Discontinued core/entered ext. | 48 | 26 | 3 |
| Completed | 99 | 107 | 99 |
| Not completed | 184 | 175 | 182 |
| Withdrew: Abnormal laboratory values | 3 | 9 | 9 |
| Withdrew: Abnormal test procedures | 1 | 0 | 1 |
| Withdrew: Condition no longer requires study drug | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 31 | 29 | 34 |
| Withdrew: Lost to follow-up | 6 | 6 | 3 |
| Withdrew: Death | 3 | 9 | 3 |
| Withdrew: Disease progression | 10 | 2 | 4 |
| Withdrew: Protocol violation | 6 | 15 | 11 |
| Withdrew: Sub optimal response or treat. failure | 19 | 11 | 13 |
| Withdrew: Administrative problems | 14 | 14 | 12 |
| Withdrew: Adverse event | 43 | 53 | 89 |
| Withdrew: Disc. core/entered ext. - dp progression | 2 | 0 | 0 |
| Withdrew: Disc. core/entered ext.- sor/tf | 46 | 26 | 3 |
| Milestone | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Started | 48 | 26 | 3 |
| Completed | 21 | 12 | 2 |
| Not completed | 27 | 14 | 1 |
| Withdrew: Adverse event | 9 | 5 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 8 | 6 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Disease progression | 2 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 2 | 0 |
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation | 22.3 (17.6 to 27.6) | 44.3 (38.4 to 50.3) | 42.7 (36.8 to 48.7) |
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Sokal risk group = Low | 26.0 (17.9 to 35.5) | 40.8 (31.2 to 50.9) | 53.4 (43.3 to 63.3) |
| Sokal risk group = Interm. | 22.8 (15.0 to 32.2) | 50.5 (40.4 to 60.6) | 40.0 (30.3 to 50.3) |
| Sokal risk group = High | 16.7 (9.2 to 26.8) | 41.0 (30.0 to 52.7) | 32.1 (21.9 to 43.6) |
Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Rates of Durable MMR at 24 Months Between All 3 Arms | 20.5 (15.9 to 25.7) | 41.8 (36.0 to 47.8) | 39.1 (33.4 to 45.1) |
CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as "Nocomplete cytogenetic response".
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| CCyR at M12 | 55.5 | 70.2 | 68.7 |
| CCyR at M24 | 61.5 | 66.0 | 66.2 |
| CCyR at M36 | 14.1 | 9.2 | 12.8 |
| CCyR at M48 | 11.3 | 8.9 | 13.5 |
| CCyR at M60 | 2.5 | 2.8 | 2.8 |
| CCyR at M72 | 1.8 | 1.8 | 2.8 |
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.
| Percentage of participants | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|
| Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms | 44.3 (38.4 to 50.3) | 42.7 (36.8 to 48.7) |
MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| MMR at M6 | 12.0 (8.5 to 16.4) | 33.0 (27.5 to 38.8) | 29.5 (24.3 to 35.2) |
| MMR at M12 | 22.3 (17.6 to 27.6) | 44.7 (38.8 to 50.7) | 43.1 (37.2 to 49.1) |
| MMR at M24 | 37.5 (31.8 to 43.4) | 61.7 (55.8 to 67.4) | 59.1 (53.1 to 64.9) |
| MMR at M36 | 38.5 (32.8 to 44.5) | 59.2 (53.2 to 65.0) | 57.3 (51.3 to 63.2) |
| MMR at M48 | 43.8 (38.0 to 49.8) | 59.9 (54.0 to 65.7) | 55.2 (49.1 to 61.1) |
| MMR at M60 | 49.1 (43.2 to 55.1) | 62.8 (56.8 to 68.4) | 61.2 (55.2 to 66.9) |
| MMR at M72 | 41.7 (35.9 to 47.7) | 52.5 (46.5 to 58.4) | 57.7 (51.6 to 63.5) |
| MMR at M84 | 40.3 (34.5 to 46.3) | 50.0 (44.0 to 56.0) | 50.9 (44.9 to 56.9) |
| MMR at M96 | 37.5 (31.8 to 43.4) | 46.1 (40.2 to 52.1) | 46.3 (40.3 to 52.3) |
| MMR at M108 | 37.5 (31.8 to 43.4) | 43.3 (37.4 to 49.3) | 40.2 (34.4 to 46.2) |
| MMR at M120 | 36.4 (30.8 to 42.3) | 37.9 (32.3 to 43.9) | 39.1 (33.4 to 45.1) |
Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Molecular response of <=0.01% at 6 months | 1.1 (0.2 to 3.1) | 8.9 (5.8 to 12.8) | 5.7 (3.3 to 9.1) |
| Molecular response of <=0.01% at 12 months | 3.9 (2.0 to 6.8) | 12.1 (8.5 to 16.4) | 8.9 (5.8 to 12.9) |
| Molecular response of <=0.01% at 24 months | 10.2 (7.0 to 14.4) | 24.5 (19.6 to 29.9) | 22.1 (17.4 to 27.4) |
| Molecular response of <=0.01% at 36 months | 14.1 (10.3 to 18.7) | 29.4 (24.2 to 35.1) | 23.8 (19.0 to 29.3) |
| Molecular response of <=0.01% at 48 months | 19.8 (15.3 to 24.9) | 33.0 (27.5 to 38.8) | 29.9 (24.6 to 35.6) |
| Molecular response of <=0.01% at 60 months | 31.1 (25.7 to 36.8) | 47.9 (41.9 to 53.9) | 43.4 (37.5 to 49.4) |
| Molecular response of <=0.01% at 72 months | 27.2 (22.1 to 32.8) | 44.3 (38.4 to 50.3) | 45.2 (39.3 to 51.2) |
| Molecular response of <=0.01% at 84 months | 29.0 (23.8 to 34.6) | 42.9 (37.1 to 48.9) | 40.6 (34.8 to 46.6) |
| Molecular response of <=0.01% at 96 months | 28.3 (23.1 to 33.9) | 39.7 (34.0 to 45.7) | 38.1 (32.4 to 44.0) |
| Molecular response of <=0.01% at 108 months | 32.2 (26.7 to 37.9) | 40.4 (34.6 to 46.4) | 34.9 (29.3 to 40.8) |
| Molecular response of <=0.01% at 120 months | 28.3 (23.1 to 33.9) | 35.5 (29.9 to 41.4) | 33.8 (28.3 to 39.7) |
This is the molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Molecular response of <=0.0032% at 6 months | 0.0 (0.0 to 1.3) | 3.5 (1.7 to 6.4) | 1.4 (0.4 to 3.6) |
| Molecular response of <=0.0032% at 12 months | 0.4 (0.0 to 2.0) | 4.6 (2.5 to 7.8) | 5.0 (2.8 to 8.2) |
| Molecular response of <=0.0032% at 24 months | 2.8 (1.2 to 5.5) | 12.4 (8.8 to 16.8) | 7.8 (5.0 to 11.6) |
| Molecular response of <=0.0032% at 36 months | 8.1 (5.2 to 11.9) | 13.8 (10.0 to 18.4) | 12.1 (8.5 to 16.5) |
| Molecular response of <=0.01032 at 48 months | 10.2 (7.0 to 14.4) | 16.3 (12.2 to 21.2) | 17.1 (12.9 to 22.0) |
| Molecular response of <=0.0032% at 60 months | 19.8 (15.3 to 24.9) | 32.3 (26.8 to 38.1) | 29.5 (24.3 to 35.2) |
| Molecular response of <=0.0032% at 72 months | 18.0 (13.7 to 23.0) | 31.2 (25.8 to 37.0) | 28.8 (23.6 to 34.5) |
| Molecular response of <=0.0032% at 84 months | 19.1 (14.7 to 24.2) | 31.6 (26.2 to 37.3) | 28.8 (23.6 to 34.5) |
| Molecular response of <=0.01% at 96 months | 23.3 (18.5 to 28.7) | 31.9 (26.5 to 37.7) | 32.4 (26.9 to 38.2) |
| Molecular response of <=0.0032% at 108 months | 24.0 (19.2 to 29.4) | 31.9 (26.5 to 37.7) | 28.1 (22.9 to 33.8) |
| Molecular response of <=0.0032% at 120 months | 21.2 (16.6 to 26.4) | 27.0 (21.9 to 32.5) | 25.6 (20.6 to 31.1) |
Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Time to First MMR | 14.13 (11.60 to 17.31) | 8.31 (6.21 to 8.48) | 8.53 (8.31 to 11.07) |
Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Duration of MMR | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| time to first molecular response of <=0.01% | 30.46 (24.11 to 36.01) | 19.38 (16.62 to 22.34) | 22.70 (19.48 to 27.63) |
| time to first molecular response of <=0.0032% | 37.29 (33.45 to 41.63) | 32.46 (23.23 to 38.67) | 35.94 (30.39 to 41.00) |
It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| duration of first molecular response of <=0.01% | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| duration of first molecular response of <=0.0032% | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Complete hematologic response (CHR) by M12 | 93.3 (89.7 to 95.9) | 90.1 (86.0 to 93.3) | 89.0 (84.7 to 92.4) |
| CHR by M24 | 93.6 (90.1 to 96.2) | 90.8 (86.8 to 93.9) | 90.4 (86.3 to 93.6) |
| CHR Overall | 94.0 (90.6 to 96.5) | 92.2 (88.4 to 95.0) | 90.7 (86.7 to 93.9) |
Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Time to Complete Cytogenic Response (CCyR) | 8.5 (5.8 to 10.9) | 5.7 (5.6 to 5.7) | 5.7 (5.7 to 5.8) |
Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Duration of CCyR | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Progression-free Survival (PFS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Event-free Survival (EFS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Actual dose intensity is defined as total dose over time on treatment
| mg/day | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Actual Dose-intensity | 400.0 (206 to 800) | 591.1 (186 to 699) | 758.9 (232 to 800) |
Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.
| Months | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Time to Progression to AP/BC | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Cmax is defined as the maximum serum concentration after dose
| ng/mL | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|
| Pharmacokinetics: Cmax | 1555 (1340 to 2300) | 1440 (1002 to 2125) |
Cmin is defined as the minimum serum concentration after dose
| ng/mL | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|
| Pharmacokinetics: Cmin | 1430 (1250 to 1740) | 915 (752 to 2080) |
Tmax is defined as the sampling time when maximum measured serum concentration occurs
| hour (h) | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|
| Pharmacokinetics: Tmax | 1.47 (0.50 to 2.04) | 1.50 (0.00 to 2.02) |
AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method
| h.ng/mL | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|
| Pharmacokinetics: AUC0-last | 14446 (12806 to 17411) | 11689 (7925 to 18678) |
Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension) | 83.3 (69.8 to 92.5) | 84.6 (65.1 to 95.6) | 66.7 (9.4 to 99.2) |
Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension) | 72.9 (58.2 to 84.7) | 73.1 (52.2 to 88.4) | 66.7 (9.4 to 99.2) |
Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension) | 64.6 (49.5 to 77.8) | 73.1 (52.2 to 88.4) | 66.7 (9.4 to 99.2) |
Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension) | 43.8 (29.5 to 58.8) | 57.7 (36.9 to 76.6) | 33.3 (0.8 to 90.6) |
Molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension) | 35.4 (22.2 to 50.5) | 38.5 (20.2 to 59.4) | 33.3 (0.8 to 90.6) |
This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.
| Percentage of participants | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension) | 20.8 | 11.5 | 33.3 |
On treatment deaths were collected from first patient first visit up to 28 days after study treatment discontinuation (approx. 11 years). Patients with cancer were also followed up for overall survival until the end of the trial (to collect any deaths occurring more than 28 days after study drug discontinuation). In this study, one death was collected after randomization but before the participant received study drug.
| deaths | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID |
|---|---|---|---|
| On-treatment deaths | 4 | 10 | 5 |
| Total deaths | 29 | 32 | 23 |
Collected over Adverse Event (AE) time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 28 days post treatment, up to maximum duration of approx. 11 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib 400 mg QD | 4/280 (1.4%) | 96/280 (34.3%) | 275/280 (98.2%) |
| Nilotinib 300 mg BID | 10/279 (3.6%) | 112/279 (40.1%) | 276/279 (98.9%) |
| Nilotinib 400 mg BID | 5/277 (1.8%) | 126/277 (45.5%) | 272/277 (98.2%) |
| All Patients | 19/836 (2.3%) | 334/836 (40%) | 823/836 (98.4%) |
| Event | Imatinib 400 mg QD | Nilotinib 300 mg BID | Nilotinib 400 mg BID | All Patients |
|---|---|---|---|---|
| Angina pectorisCardiac disorders | 1/280 | 3/279 | 11/277 | 15/836 |
| Coronary artery diseaseCardiac disorders | 1/280 | 4/279 | 10/277 | 15/836 |
| PneumoniaInfections and infestations | 9/280 | 6/279 | 6/277 | 21/836 |
| Myocardial infarctionCardiac disorders | 2/280 | 4/279 | 6/277 | 12/836 |
| Abdominal painGastrointestinal disorders | 2/280 | 5/279 | 6/277 | 13/836 |
| Back painMusculoskeletal and connective tissue disorders | 2/280 | 2/279 | 6/277 | 10/836 |
| PyrexiaGeneral disorders | 2/280 | 6/279 | 5/277 | 13/836 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 5/280 | 6/279 | 0/277 | 11/836 |
| AnaemiaBlood and lymphatic system disorders | 4/280 | 2/279 | 5/277 | 11/836 |
| Acute myocardial infarctionCardiac disorders | 0/280 | 2/279 | 5/277 | 7/836 |
| Event | Imatinib 400 mg QD | Nilotinib 300 mg BID | Nilotinib 400 mg BID | All Patients |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 137/280 | 60/279 | 67/277 | 264/836 |
| RashSkin and subcutaneous tissue disorders | 70/280 | 112/279 | 125/277 | 307/836 |
| NauseaGastrointestinal disorders | 120/280 | 64/279 | 89/277 | 273/836 |
| HeadacheNervous system disorders | 76/280 | 97/279 | 105/277 | 278/836 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 99/280 | 40/279 | 39/277 | 178/836 |
| Alanine aminotransferase increasedInvestigations | 39/280 | 83/279 | 87/277 | 209/836 |
| NasopharyngitisInfections and infestations | 69/280 | 82/279 | 67/277 | 218/836 |
| VomitingGastrointestinal disorders | 80/280 | 46/279 | 61/277 | 187/836 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 67/280 | 74/279 | 65/277 | 206/836 |
| AnaemiaBlood and lymphatic system disorders | 71/280 | 38/279 | 45/277 | 154/836 |
Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.
| Age, Customized(Participants) | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID | Total |
|---|---|---|---|---|
| <35 years | 63 | 67 | 65 | 195 |
| >= 35 - <45 years | 67 | 50 | 59 | 176 |
| >=45 - <55 years | 63 | 72 | 65 | 200 |
| >=55 - < 65 years | 55 | 57 | 65 | 177 |
| >=65 years | 35 | 36 | 27 | 98 |
| Sex: Female, Male(Participants) | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID | Total |
|---|---|---|---|---|
| Female | 125 | 124 | 106 | 355 |
| Male | 158 | 158 | 175 | 491 |
| Race/Ethnicity, Customized(Participants) | Imatinib 400 mg QD | Nilotinb 300 mg BID | Nilotinib 400 mg BID | Total |
|---|---|---|---|---|
| Caucasian | 187 | 170 | 185 | 542 |
| Black | 7 | 12 | 11 | 30 |
| Asian | 71 | 76 | 66 | 213 |
| Native American | 1 | 0 | 2 | 3 |
| Other | 17 | 24 | 17 | 58 |
Showing the first 100 of 213 sites across 35 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2007 to primary completion in Sep 2009, 25 months.
Results were first posted in Jun 2013, 3 years 9 months after primary completion.
Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nilotinib · Imatinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →